Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant?

Transplantation

Volumn 87, Issue 12, 2009, Pages 1897-1898

  Aubert, Vincent ^a   Venetz, Jean Pierre ^a   Pantaleo, Giuseppe ^a   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ASSAY; B LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; PLASMAPHERESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

B-LYMPHOCYTES; HUMANS; ISOANTIBODIES; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 67649583460     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a98eef     Document Type: Letter

References (3)

1. Lefaucheur C, Superbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
2. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160.
3. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients.AmJ Transplant 2007; 7: 1027.